Search Results: PARP

One of the biggest meetings of the world’s cancer specialists took place this weekend. Usually located in Chicago, researchers and clinicians around the world met virtually this year to present the latest in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting. Here’s a flavour of the some of the top research presented.

Recently, news of a COVID-19 vaccine has dominated headlines. We’ve summarised all the information that is out there, with rolling updates, in our new vaccine blog post.

This year’s event took place virtually on Wednesday 12 May. Watch or listen back now.

Almost 20 years since Cancer Research UK was founded, not many who worked with McVie remain, but staff know him as the man who gave the charity its beginning.

A new targeted treatment has been recommended by the National Institute of Health and Care Excellence for some adults with ovarian cancer.

25 years ago, a team of our scientists were celebrating. Their risky strategy had paid off.

Due to the effects of COVID-19, Cancer Research UK has had to cut its research funding by £45 million.

Today’s new figures, from the UK’s National Cancer Research Institute, project a devastating 24% drop in the UK’s overall cancer research spending this year, driven by a 46% fall in charity sector funding.

How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors.

A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.